Boule Diagnostics AB will publish the interim report for the period January–March 2020 at 15:00, Thursday, May 7th, 2020. Following the publication, Boule will hold a conference call at 16:00 for media and investors.
CFO and acting CEO Christina Rubenhag will present and comment on the interim report. After the presentation there will be time for audience questions. The presentation will be held in English.
Time: 16:00 CET, Thursday, May 7th, 2020
Telephone number: +46(0) 8-744 77 22
The interim report will be accessible at http://www.boule.com when published.
Please feel free to attend this event!
For further information, please contact:
Christina Rubenhag, CFO and acting CEO and President,
Boule Diagnostics AB, phone +46(0) 705-46 72 22
About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com
The information was submitted for publication, through the agency of the contact person set out above,
at 15.00 CET on May 5, 2020.